Skip to main content
Evidence Snapshot

TEC family kinase

CHEMBL4296642 PROTEIN FAMILY Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296642
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats TEC family kinase as ChEMBL target CHEMBL4296642, mapped to UniProt Q08881. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
TEC family kinase
PROTEIN FAMILY · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4296642
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q08881
Tyrosine-protein kinase ITK/TSK
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why TEC family kinase matters

As of 2026-09-13

TEC family kinase is reviewed as Tyrosine-protein kinase ITK/TSK (UniProt Q08881); TEC family kinase shows approved-linked disease relevance led by alopecia areata. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded..

Protein context
Tyrosine-protein kinase ITK/TSK

Tyrosine-protein kinase ITK/TSK Sequence length is 620 aa.

Review this target as TEC family kinase, mapped to UniProt Q08881. ChEMBL maps the protein component as Tyrosine-protein kinase ITK/TSK. Sequence length is 620 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt Q08881 Protein
Disease context
alopecia areata

TEC family kinase shows approved-linked disease relevance led by alopecia areata. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include RITLECITINIB, RITLECITINIB TOSYLATE.

Start review with alopecia areata because it currently carries approved-linked support. Linked drugs include RITLECITINIB, RITLECITINIB TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why TEC family kinase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q08881, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why alopecia areata is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types

pChEMBL Activity Distribution

← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T20:45:14Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4296642